Resonance Health Ltd extends services for global clinical trial
(MENAFN- ProactiveInvestors - Australia)
Resonance Health Ltd (ASX:RHT) has extended its involvement in a pharmaceutical company";s Phase 3 global clinical trial by providing additional analytical services.
Resonance specialises in the delivery of quantitative magnetic resonance imaging (MRI) techniques for the diagnosis and clinical management of human diseases.
The company offers ‘FerriScan"; for the quantitative measurement of liver iron concentration and ‘Cardiac T2*"; for the assessment of heart iron loading.
The two year collaboration with the pharma company was announced in June 2016 for the provision of FerriScan and Cardiac T2* analysis services for the Asia-based component of a global trial.
The collaboration has now been extended to include a European-based country commencing participation in the study.
Moreover, Resonance will provide a new service in the form of a ‘Spleen Volume Measurement";, to assist in the detection of hypersplenism.
Resonance";s revenue from ordinary activities for the year ended 30 June 2016 was $2.5 million, an increase of 4% from 2015.
The company closed its books for the year with $2.5 million in cash.
Resonance";s shares rose 42% during the last 3 months, last trading at $0.027. <
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.